
    PURDUE PHARMACEUTICAL PRODUCTS L.P., Purdue Pharma L.P., Transcept Pharmaceuticals, Inc., nka Paratek Pharmaceuticals, Inc., Plaintiffs-Appellants v. ACTAVIS ELIZABETH LLC, Novel Laboratories, Inc., Dr. Reddy’s Laboratories, Inc., Dr. Reddy’s Laboratories, Ltd., Defendants-Appellees PAR Pharmaceutical, Inc., TWI Pharmaceuticals, Inc., Defendants.
    No. 2015-1659.
    United States Court of Appeals, Federal Circuit.
    Jan. 8, 2016.
    Christopher Neil Sipes, Covington & Burling LLP, Washington, DC, argued for plaintiffs-appellants. Aso represented by Erica Nicole Andersen, Michael N. Kennedy.
    Jacob M. Holdreith, Robins Kaplan LLP, Minneapolis, MN, argued for all defendants-appellees. Defendant-appellee Novel Laboratories, Inc. also represented by Miles Finn, Jeffrey Aan Hovden, Oren D. Langer, New York, NY.
    Samuel S. Park, Winston & Strawn LLP, Chicago, IL, for defendant-appellee Actavis Elizabeth LLC. Aso represented by Dan Hoang; Charles B. Klein, Washington, DC.
    Jeffrey B. Anold, Cantor Colburn LLP, Atlanta, GA, for defendants-appellees Dr. Reddy’s Laboratories, Inc., Dr. Reddy’s Laboratories, Ltd. Aso represented by Steven M. Coyle, Nicholas Geiger, Hartford, CT.
    LOURIE, DYK, and HUGHES, Circuit Judges.
   JUDGMENT

PER CURIAM.

This Cause having been heard and considered, it is Ordered and Adjudged:

AFFIRMED. See Fed. Cir. R. 36.  